A three-judge panel on the 5th U.S. Circuit Court of Appeals ruled Friday to block doctors from prescribing the abortion pill mifepristone through telehealth and prohibited dispensing the drug through the mail, reinstating a 2021 requirement that the medication be prescribed and dispensed in person. The ruling reverses a Biden administration policy that had allowed access through telehealth prescriptions and mail delivery.

The decision drew immediate condemnation from Democratic lawmakers who argued it would significantly restrict reproductive care nationwide, particularly in rural areas and states where telehealth has expanded since the COVID-19 pandemic. Mifepristone was approved by the Food and Drug Administration (FDA) in 2000 and is typically used in combination with misoprostol for medication abortion.

What the Left Is Saying

Rep. Ayanna Pressley (D-Mass.) called the ruling a decision made by 'a court packed with Trump-appointed extremists' to make medication abortion harder to access. In a statement posted to X, she wrote: 'Let's be clear: mifepristone is safe, effective & FDA approved.' She added: 'We won't stop fighting to protect our reproductive freedom & this basic, essential form of healthcare.'

Sen. Patty Murray (D-Wash.) argued the decision disregards clinical evidence and federal oversight. 'The Fifth Circuit just told millions of women that three judges know better than the FDA, their doctors, and 25 years of evidence. They don't,' she wrote on X. 'This restriction on medication abortion is a nationwide abortion restriction, full stop.' Murray added: 'I have no intention of letting this stand.'

Sen. Amy Klobuchar (D-Minn.) highlighted geographic barriers created by the ruling. 'A Louisiana federal court just blocked access to mifepristone by mail, limiting how patients can receive an FDA-approved medication,' she said in a statement. 'This decision creates new barriers to care... We must restore women's access to health care.'

Sen. Ron Wyden (D-Ore.) framed the ruling as sweeping restrictions on abortion access. 'This ruling amounts to a nationwide abortion ban. Mifepristone is safe, full stop,' he wrote on X. He added: 'This isn't about science and protecting women, it's a calculated plot by Republicans obsessed with controlling the private health care decisions of women in America.'

Sen. Maria Cantwell (D-Wash.) warned of impacts even in states that protect abortion rights. 'Mifepristone is a safe and effective abortion medication that has been used by millions of people since the FDA approved it more than a quarter century ago,' she wrote online. 'But this ruling will restrict access to this safe medication for women in every state – including those that have repeatedly affirmed abortion rights, like Washington.' Cantwell added: 'Make no mistake, this puts women's lives and rights at risk.'

Former Health and Human Services Secretary Xavier Becerra, now running for California governor, said the decision would disproportionately affect vulnerable communities. 'Politicians and judges should not stand between a woman and her doctor,' he wrote on X. 'Blocking telehealth access to mifepristone will hit working families, rural communities, and those already facing barriers the hardest.'

Democratic Govs. Gavin Newsom (Calif.) and Gretchen Whitmer (Mich.) also criticized the ruling. 'Access to mifepristone is particularly critical for women in rural and underserved communities where healthcare access is limited,' Newsom wrote on X. He pledged: 'California will continue to fight like hell against those who seek to reach across our border to try to tear away a woman's right to choose.' Whitmer called the ban 'based on politics, not science.'

What the Right Is Saying

Republican lawmakers praised the court's ruling as restoring safeguards and strengthening oversight of abortion medication.

Sen. James Lankford (R-Okla.) argued the Biden-era policies endangered women. 'The Biden administration endangered the lives of women and girls by removing safeguards for mifepristone,' he said in a post on X. 'Today's Fifth Circuit decision takes a big step to right this wrong. Let's make sure women and girls are protected from this dangerous drug.'

Rep. Chip Roy (R-Texas) called the decision 'great news for babies' in a post on X, adding: 'Much left to do!' He wrote: 'Cutting funds to Planned Parenthood is great — but pills are the new battlefield for life.'

Several GOP-led states have challenged federal rules governing mifepristone, including after the Supreme Court upheld access to the medication in 2024. Officials in Louisiana had argued that mailing abortion pills into the state conflicted with its near-total abortion ban.

What the Numbers Show

The FDA approved mifepristone in 2000, making it a medication with over two decades of clinical use data.

According to the ruling, the 5th Circuit reinstated a 2021 requirement that mandates mifepristone be prescribed and dispensed in person — reversing pandemic-era telehealth accommodations put in place during the Biden administration.

The American Civil Liberties Union (ACLU) and the Center for Reproductive Rights both called the ruling a 'devastating setback' for reproductive care access.

Danco Laboratories, LLC, a Delaware-based pharmaceutical company that manufactures and distributes mifepristone, filed an appeal to the Supreme Court on Saturday seeking to block the appellate ruling.

The Bottom Line

The 5th Circuit decision marks a significant development in ongoing legal battles over medication abortion access. Democrats have vowed continued resistance, with some lawmakers indicating they will not let the ruling stand.

The case now heads to the Supreme Court after Danco Laboratories filed an emergency appeal Saturday asking justices to block the lower court's restrictions on telehealth prescriptions and mail dispensing of mifepristone.

Healthcare advocates warn that reinstating in-person requirements could create new barriers for patients in rural areas and states with limited clinic access. Republicans have framed the ruling as a necessary safeguard for women's health.

What to watch: Whether the Supreme Court agrees to hear Danco's emergency appeal, and how lower courts rule on similar challenges from other GOP-led states.